NASDAQ:EOLS Evolus Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $11.74 +0.05 (+0.43%) (As of 07/5/2022 10:28 AM ET) Add Compare Share Today's Range$11.50▼$11.7450-Day Range$10.22▼$13.9452-Week Range$5.06▼$14.34Volume3,387 shsAverage Volume425,413 shsMarket Capitalization$658.03 millionP/E RatioN/ADividend YieldN/APrice Target$15.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Evolus MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside31.2% Upside$15.33 Price TargetShort InterestHealthy7.16% of Float Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$1.54 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.07) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.81 out of 5 starsMedical Sector739th out of 1,428 stocksPharmaceutical Preparations Industry363rd out of 680 stocks 3.4 Analyst's Opinion Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.33, Evolus has a forecasted upside of 31.2% from its current price of $11.69.Amount of Analyst CoverageEvolus has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.16% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Evolus has recently decreased by 13.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Previous Next 2.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEvolus has received a 40.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private dermatologist's appointments", "Private internist's appointments", and "Botulinum toxin" products. See details.Environmental SustainabilityThe Environmental Impact score for Evolus is -1.27. Previous Next 1.6 News and Social Media Coverage News SentimentEvolus has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Evolus this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Evolus to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,538,305.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Evolus is held by insiders.Percentage Held by InstitutionsOnly 36.94% of the stock of Evolus is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($1.07) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvolus has a P/B Ratio of 7.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Email Address About Evolus (NASDAQ:EOLS) StockEvolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Read More EOLS Stock News HeadlinesJune 26, 2022 | americanbankingnews.comBrokerages Set Evolus, Inc. (NASDAQ:EOLS) Price Target at $15.33June 24, 2022 | finance.yahoo.comInvestors in Evolus (NASDAQ:EOLS) have unfortunately lost 15% over the last three years - Yahoo FinanceJuly 5, 2022 | Investing Trends (Ad)All Electric Commitment From GM, Volkswagen, Could Put Lithium Stock In A SupercycleMore automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...June 24, 2022 | finance.yahoo.comNeedham Is Bullish On This Botox Equivalent Aesthetics CompanyJune 24, 2022 | finance.yahoo.comInvestors in Evolus (NASDAQ:EOLS) have unfortunately lost 15% over the last three yearsJune 23, 2022 | seekingalpha.comEvolus attracts buy rating from Needham at $18 price target (NASDAQ:EOLS) - Seeking AlphaJune 23, 2022 | benzinga.comNeedham Initiates Coverage On Evolus with Buy Rating, Announces Price Target of $18 - Benzinga - BenzingaJune 10, 2022 | benzinga.comEvolus's Return On Capital Employed Overview - Benzinga - BenzingaJuly 5, 2022 | Investing Trends (Ad)All Electric Commitment From GM, Volkswagen, Could Put Lithium Stock In A SupercycleMore automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...June 10, 2022 | finance.yahoo.comDoes Evolus, Inc. (EOLS) Have the Potential to Rally 28% as Wall Street Analysts Expect? - Yahoo FinanceJune 8, 2022 | nasdaq.comIs Computer Programs and Systems (CPSI) Stock Outpacing Its Medical Peers This Year? - NasdaqJune 8, 2022 | nasdaq.comDoes Evolus, Inc. (EOLS) Have the Potential to Rally 28% as Wall Street Analysts Expect? - NasdaqJune 8, 2022 | finance.yahoo.comIs Computer Programs and Systems (CPSI) Stock Outpacing Its Medical Peers This Year?June 8, 2022 | finance.yahoo.comDoes Evolus, Inc. (EOLS) Have the Potential to Rally 28% as Wall Street Analysts Expect?June 2, 2022 | streetinsider.comEvolus (EOLS) Reports Publication of Post Hoc Analysis Showing Jeuveau Highly Effective for Millennials - StreetInsider.comMay 29, 2022 | benzinga.comEOLS SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Evolus, Inc. and Encourages Long-Term EOLS Shareholders to Contact the Firm - BenzingaMay 23, 2022 | finance.yahoo.comHas Evolus (EOLS) Outpaced Other Medical Stocks This Year?May 23, 2022 | finance.yahoo.comWall Street Analysts Predict a 34% Upside in Evolus, Inc. (EOLS): Here's What You Should KnowMay 18, 2022 | businesswire.comEvolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States - Business WireMay 12, 2022 | benzinga.comBarclays Upgrades Evolus to Equal-Weight, Raises Price Target to $10 - Benzinga - BenzingaMay 11, 2022 | streetinsider.comEvolus to Participate in the HC Wainwright Global Investment Conference - StreetInsider.comMay 11, 2022 | finance.yahoo.comEvolus to Participate in the H.C. Wainwright Global Investment Conference - Yahoo FinanceMay 11, 2022 | finance.yahoo.comEvolus Reports First Quarter 2022 Results and Provides Business Update - Yahoo FinanceMay 11, 2022 | nasdaq.comEvolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates - NasdaqMay 10, 2022 | seekingalpha.comEvolus GAAP EPS of -$0.31 beats by $0.12, revenue of $33.91M beats by $4.08M (NASDAQ:EOLS) - Seeking AlphaMay 10, 2022 | businesswire.comEvolus Reports First Quarter 2022 Results and Provides Business Update - Business WireMay 10, 2022 | finance.yahoo.comIs Evolus (NASDAQ:EOLS) Using Too Much Debt?See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EOLS CUSIPN/A CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees167Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today7/05/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$15.33 High Stock Price Forecast$20.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+30.6%Consensus RatingModerate Buy Rating Score (0-4)2.83333333333333 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,810,000.00 Net Margins-58.28% Pretax Margin-58.25% Return on Equity-80.20% Return on Assets-30.31% Debt Debt-to-Equity Ratio1.06 Current Ratio3.51 Quick Ratio3.42 Sales & Book Value Annual Sales$99.67 million Price / Sales6.60 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book7.99Miscellaneous Outstanding Shares56,050,000Free Float51,789,000Market Cap$658.03 million OptionableOptionable Beta2.05 Evolus Frequently Asked Questions Should I buy or sell Evolus stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Evolus stock. View analyst ratings for Evolus or view top-rated stocks. What is Evolus' stock price forecast for 2022? 6 equities research analysts have issued 12-month price targets for Evolus' stock. Their EOLS stock forecasts range from $10.00 to $20.00. On average, they expect Evolus' stock price to reach $15.33 in the next twelve months. This suggests a possible upside of 30.7% from the stock's current price. View analysts' price targets for Evolus or view top-rated stocks among Wall Street analysts. How has Evolus' stock performed in 2022? Evolus' stock was trading at $6.51 on January 1st, 2022. Since then, EOLS shares have increased by 80.2% and is now trading at $11.73. View the best growth stocks for 2022 here. When is Evolus' next earnings date? Evolus is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for Evolus. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) announced its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.24. The firm had revenue of $33.90 million for the quarter, compared to the consensus estimate of $29.83 million. Evolus had a negative trailing twelve-month return on equity of 80.20% and a negative net margin of 58.28%. The company's quarterly revenue was up 177.9% on a year-over-year basis. During the same period last year, the company earned $0.16 earnings per share. View Evolus' earnings history. What guidance has Evolus issued on next quarter's earnings? Evolus issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $150.00 million-$150.00 million, compared to the consensus revenue estimate of $148.47 million. Who are Evolus' key executives? Evolus' management team includes the following people: Mr. David Moatazedi, Pres, CEO & Director (Age 44, Pay $1.23M) (LinkedIn Profile)Dr. Rui Avelar C.CFP, Dip.SportMed, M.D., Chief Medical Officer and Head of R&D (Age 60, Pay $660.08k)Mr. David K. Erickson, VP of Investor RelationsMr. Jeffrey J. Plumer, Gen. CounselMr. Kurt Knab, VP of SalesMs. Crystal Muilenburg, Chief Marketing Officer (Age 42)Ms. Jessica Novak, Sr. VP of HR What is David Moatazedi's approval rating as Evolus' CEO? 1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among Evolus' employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Evolus' key competitors? Some companies that are related to Evolus include Pacira BioSciences (PCRX), HUTCHMED (HCM), Insmed (INSM), ACADIA Pharmaceuticals (ACAD), EQRx (EQRX), Arvinas (ARVN), Global Blood Therapeutics (GBT), Schrödinger (SDGR), Arcus Biosciences (RCUS), Sage Therapeutics (SAGE), ChemoCentryx (CCXI), Ironwood Pharmaceuticals (IRWD), OPKO Health (OPK), Xencor (XNCR) and Aurinia Pharmaceuticals (AUPH). View all of EOLS's competitors. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), OrganiGram (OGI) and Bionano Genomics (BNGO). When did Evolus IPO? (EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. What is Evolus' stock symbol? Evolus trades on the NASDAQ under the ticker symbol "EOLS." How do I buy shares of Evolus? Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Evolus' stock price today? One share of EOLS stock can currently be purchased for approximately $11.73. How much money does Evolus make? Evolus (NASDAQ:EOLS) has a market capitalization of $657.47 million and generates $99.67 million in revenue each year. The company earns $-46,810,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. How many employees does Evolus have? Evolus employs 167 workers across the globe. How can I contact Evolus? Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for Evolus is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at ir@evolus.com. This page (NASDAQ:EOLS) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
